Overactive bladder

Published studies find low documented adherence to guideline-based care for female urinary incontinence

Retrieved on: 
Friday, July 22, 2022
Diagnosis, Obstetrics & Gynecology (journal), Instagram, Use, UI, Adult, SUFU, Cough, LinkedIn, American Urological Association, American College of Obstetricians and Gynecologists, AUA, American College, Obstetrics, Smartphone, Research, Woman, PFMT, Solution, Pelvic floor, Medical Affairs Bureau, Society, Urinary incontinence, Doctor of Pharmacy, All rights reserved, Storey, Engineering, Physician, Overactive bladder, Twitter, Female, ACOG, Sexual dysfunction, Health, Femtech, Quality of life, PDT, FDA, DPT, MUI, FI, Exertion, SUI, Sneeze, Feces, Time, MPH, Urine, Hotel manager, Rehabilitation, Physical, Movement, Mental health, Senior, Patient, PT, Medical device, Medical imaging, Health insurance, Birth control, Gynaecology, Kegel exercise, Gynaecology, Facebook, Urodynamic testing

BOSTON, July 22, 2022 /PRNewswire/ -- Renovia Inc. (Renovia), a developer of non-surgical treatments for female pelvic floor disorders and an advocate for women's health, announced today that Neurourology and Urodynamics published two studies demonstrating low rates of documented adherence to treatment guidelines for female urinary incontinence (UI) care for women and the effect on payer costs. One study showed significantly higher costs for payers in the two years following diagnosis for women whose treatment claims did not align with published guidelines for female UI. A second study showed very low use of physical therapy (PT) for UI, a discipline commonly engaged in first-line care for UI.

Key Points: 
  • BOSTON, July 22, 2022 /PRNewswire/ -- Renovia Inc. (Renovia), a developer of non-surgical treatments for female pelvic floor disorders and an advocate for women's health, announced today that Neurourology and Urodynamics published two studies demonstrating low rates of documented adherence to treatment guidelines for female urinary incontinence (UI) care for women and the effect on payer costs.
  • A second study showed very low use of physical therapy (PT) for UI, a discipline commonly engaged in first-line care for UI.
  • Numerous studies show PFMT isan effective treatment for urinary incontinence and that PFMT, commonly referred to as Kegels, is challenging for women to implement effectively on their own.
  • The study determined that documented care not sequenced in adherence to guidelines increasedpayers' cost burden.

Axonics® to Report Second Quarter 2022 Financial Results on August 1

Retrieved on: 
Monday, July 11, 2022
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Overactive bladder, SUI, Deloitte Technology Fast 500, Patient, Woman, SNM, Interest, Webcast, Urinary incontinence, Nasdaq, Fecal incontinence, Financial Times, Telephone, Dietary supplement, Axon Enterprise

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2022 financial results after the close of trading on Monday, August 1.

Key Points: 
  • Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2022 financial results after the close of trading on Monday, August 1.
  • Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results.
  • Interested parties that would like to join the conference call by telephone are required to register in advance by visiting the following link: Axonics 2Q22 registration .
  • 1 on the 2021 Deloitte Technology Fast 500 and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.

Urovant Sciences® Named One of 2022 “Best Places to Work” in Orange County

Retrieved on: 
Thursday, July 7, 2022
Biotechnology, Health, Professional Services, Pharmaceutical, Human Resources, Liver, FDA, Patient, CEO, Adult, Nasal congestion, Orange County Business Journal, American City Business Journals, Allergy, OAB, Workforce, Feedback, Man, Nausea, Breast milk, Employment, Vibegron, American, Great Places, Urinary retention, Kidney, Gesellschaft mit beschränkter Haftung, Headache, NYSE, Organization, Urinary tract infection, Workplace, Science, Vitamin, Sore throat, The Last Best Place, Diarrhea, Overactive bladder, Medicine, Instagram, Twitter, Upper respiratory tract infection, Digoxin, Urinary incontinence, Management, Pharmaceutical industry, Dietary supplement, Urology

The recognition by the OCBJ follows on a separate recognition Urovant Sciences received in 2022, the Great Place to Work Certification.

Key Points: 
  • The recognition by the OCBJ follows on a separate recognition Urovant Sciences received in 2022, the Great Place to Work Certification.
  • Organizations from across the county entered the two-part process to determine the Best Places to Work in Orange County.
  • The Best Places to Work in Orange County list was published in the July 4 edition of the Orange County Business Journal.
  • UROVANT, UROVANT SCIENCES, GEMTESA and the UROVANT SCIENCES logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Renovia receives FDA clearance for leva® Pelvic Health System as first-line treatment for chronic fecal incontinence

Retrieved on: 
Thursday, July 7, 2022
Patient, Embarrassment, Food, Doctor of Philosophy, Social isolation, Obstetrics & Gynecology (journal), Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Urinary incontinence, FDA, Movement, MMHC, Leva, Female, Vagina, Woman, Sexual dysfunction, Birmingham, Overactive bladder, Instagram, Associate, Twitter, Exercise intolerance, Research, LinkedIn, Feces, Associate Director of National Intelligence and Chief Information Officer, PFMT, FI, Fecal incontinence, Health, Use, Reproductive health, Financial endowment, Surgery, A Call for Unity, PDT, UAB, Rectum, Professor, Depression, Rehabilitation, Risk, UI, University, Pelvic floor, All rights reserved, Femtech, Vanderbilt University Medical Center, Storey, Pharmaceutical industry, Birth control, Urology, Gynaecology, Obstetrics, Facebook, MD

BOSTON, July 7, 2022 /PRNewswire/ -- Renovia Inc. ("Renovia"), a developer of non-surgical, treatments for female pelvic floor disorders and an advocate for women's health, announced today that the U.S. Food and Drug Administration (FDA) has cleared its leva® Pelvic Health System for the first-line treatment of chronic fecal incontinence (FI) in women. The decision follows the grant of Breakthrough Device Designation by FDA in October 2021. leva had previously been cleared by FDA to treat stress, mixed and mild-to-moderate urinary incontinence (UI) in women. The new indication makes first-line, at-home treatment for FI, also called accidental bowel leakage, available to the over 12 million U.S. women who suffer from the debilitating and progressive condition.

Key Points: 
  • leva is a prescription digital therapeutic (PDT) that guides a woman through pelvic floor muscle training (PFMT).
  • In November 2019, leva was FDA cleared for the treatment of stress, mixed and mild to moderate urgency urinary incontinence (including overactive bladder) in women.
  • The leva Pelvic Health System offers a novel, non-invasive, medication-free way for women to train and strengthen their pelvic floor musclesat home in just five minutes a dayto treat urinary incontinence (UI) and chronic fecal incontinence (FI).
  • Renovia Inc. and leva are trademarks or registered trademarks of Renovia Inc. in the United States and other countries.

Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland

Retrieved on: 
Tuesday, July 5, 2022
Biotechnology, Pharmaceutical, Health, Patient, OAB, Urine, BPH, Gesellschaft mit beschränkter Haftung, Headache, Quality of life, Overactive bladder, Digoxin, Group, Urinary incontinence, Liver, FDA, Life, European Economic Area, Nasal congestion, Breast milk, NYSE, Vitamin, Sore throat, Diarrhea, Twitter, Urinary urgency, LinkedIn, Man, Urination, Partnership, Derma, Mississippi, Health, Urinary tract infection, Nausea, Pierre Fabre, USD, Adult, Allergy, BJU International, Urinary retention, Kidney, Pharmacy, Medicine, Upper respiratory tract infection, Science, Nocturia, Pharmaceutical industry, Fine chemical, Dietary supplement, Urology, VideoRay UROVs

Urovant Sciences and Pierre Fabre will share responsibility for vibegron clinical trials in the pediatric populations in Europe.

Key Points: 
  • Urovant Sciences and Pierre Fabre will share responsibility for vibegron clinical trials in the pediatric populations in Europe.
  • As part of the transaction, Urovant Sciences will also provide manufacturing services to Pierre Fabre.
  • 2011;108(7):1132-1138. doi:10.1111/j.1464-410X.2010.09993.x
    UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.
  • PIERRE FABRE, the PIERRE FABRE logo are trademarks of Pierre Fabre Medicament SAS, registered in the U.S and in other countries.

Eloxx Pharmaceuticals Announces Changes to Board of Directors

Retrieved on: 
Tuesday, July 5, 2022
Department, Financial compensation, FDA, CF, Mutation, Science, University of Chicago, Patient, Savannah State University Office of Graduate Studies and Sponsored Research, Kidney, CEO, Massachusetts Institute of Technology, United States Attorney General, GLOBE, Â, European Commission, CFA, Degenerative disease, Cancer, Initial public offering, RMAS, Eukaryotic ribosome, MBA, Department of Human Services and Health, Fast Track, Orphan, Humanitarian use licenses, Food, Autosome, BS, Royal commission, Roivant Sciences, RNA, Psoriasis, Polycystic kidney disease, University, Cystic fibrosis, Acquisition, JD, Regulation of tobacco by the U.S. Food and Drug Administration, Overactive bladder, NASDAQ, Uterine fibroid, Management, Pharmaceutical industry

WATERTOWN, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the appointment of Lindsay Androski, JD, MBA to its board of directors and as a member of the Board’s Audit Committee and Compensation Committee. Current board members Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra have stepped down from the board. Following these changes, Eloxx’s board is now comprised of five directors.

Key Points: 
  • Current board members Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra have stepped down from the board.
  • Following these changes, Eloxxs board is now comprised of five directors.
  • I am passionate about companies like Eloxx that are focused on addressing unmet needs for underserved patient populations.
  • I am excited to join the board of Eloxx and to contribute to the companys work in developing therapies for rare diseases, said Ms. Androski.

NDRI Presents Empowering Research and Discovery Award to Washington Regional Transplant Community, Recognizing Outstanding Commitment to Advancing Research

Retrieved on: 
Wednesday, June 29, 2022
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Cell, WRTC, National, TSS, Public sector banks in India, Patient, CEO, Annual general meeting, Tissue, National Disease Research Interchange, Multimedia, Association, Transplant, Pain management, Heart failure, OPOS, Publication, Partnership, NDRI, Organization, Muscular dystrophy, OPO, Culture, Overactive bladder, Time, Eye, Social media, Education, Hospital, Dentistry, Management, Pharmaceutical industry, Research

The award was presented on June 14 during the Association of Organ Procurement Organizations ( AOPO ) 2022 Annual Meeting in Phoenix, Arizona.

Key Points: 
  • The award was presented on June 14 during the Association of Organ Procurement Organizations ( AOPO ) 2022 Annual Meeting in Phoenix, Arizona.
  • At WRTC, we have created a culture of research as we believe that research also saves lives.
  • Specifically in 2021, the organization facilitated the placement of 121 organs for research and education from 120 research authorized donors.
  • The National Disease Research Interchange (NDRI) is the nations leading source of human tissues, cells, and organs for scientific research.

Published health economics study shows improved treatment for female urinary incontinence may have positive effect on patient outcomes and healthcare costs

Retrieved on: 
Tuesday, June 21, 2022
PT, Rehabilitation, Cough, Pelvic floor, Smartphone, LinkedIn, Obstetrics, Urine, University, Keck School of Medicine of USC, Health, MUI, Associate, Urinary incontinence, Division, Obstetrics & Gynecology (journal), Incontinence, Therapy, Female, UI, Use, Storey, PDT, Sneeze, Twitter, Movement, PFMT, FDA, Urogynecology, All rights reserved, Medical Affairs Bureau, Sexual dysfunction, Exertion, SUI, Adult, Patient, Multimedia, Instagram, Woman, Safety, Research, Kegel exercise, Overactive bladder, Femtech, Pharmaceutical industry, Health insurance, Birth control, Medical imaging, Gynaecology, Urodynamic testing, Medicine, Facebook

BOSTON, June 21, 2022 /PRNewswire/ -- Renovia Inc. (Renovia), a women-led company that develops digital therapeutics for female pelvic floor disorders, announced today that a recent peer-reviewed, published study showed that women with stress urinary incontinence (SUI) and mixed urinary incontinence (MUI) consume significantly more medical resources and incur higher costs to payers, compared to women without SUI/MUI.  The study was published in Neurourology and Urodynamics, the official journal of the Society of Urodynamics and Female Pelvic Medicine & Urogenital Reconstruction.

Key Points: 
  • The study was published in Neurourology and Urodynamics , the official journal of the Society of Urodynamics and Female Pelvic Medicine & Urogenital Reconstruction.
  • The study, "Healthcare Resource Use and Cost Burden of Urinary Incontinence to United States Payers," assessed healthcare resource utilization and costs for female patients diagnosed with stress or mixed urinary incontinence (SUI/MUI) compared to a 1:1 matched cohort of patients without SUI/MUI.
  • Urinary incontinence (UI) is a highly prevalent health condition experienced by over 60% of adult women.
  • Multiple studies show that Pelvic Floor Muscle Training (PFMT), commonly referred to as Kegel exercises, can offer effective, first-line treatment for urinary incontinence.

Bright Uro Launches with $6 Million in Seed Financing and Grant from National Institutes of Health

Retrieved on: 
Thursday, June 9, 2022
Biotechnology, General Health, Health, Medical Devices, Phase II, Urodynamic testing, Uro, OAB, Urine, Overactive bladder, Standard of care, CEO, NIH, Urology, United States Department of Veterans Affairs, Non-functional testing, Physician, Health, BPH, National, Patient, Technology, Cleveland Clinic, Diagnosis, Special operations, Case Western Reserve University, Department, Efficiency, LUTS, Parker Hannifin, Pharmaceutical industry, Medical imaging, Gleaning

Bright Uro was also awarded a $2 million Phase II SBIR grant from the National Institutes of Health (NIH).

Key Points: 
  • Bright Uro was also awarded a $2 million Phase II SBIR grant from the National Institutes of Health (NIH).
  • Bright Uro fulfills the promise of digital health, with more accurate and flexible diagnosis, at a decreased cost.
  • Bright Uros Glean Urodynamics System is designed to improve the patient and clinician experience with increased accuracy and comfort.
  • Bright Uro has obtained exclusivity to the catheter-free method used with the Glean system through a licensing agreement with Cleveland Clinic.

The Worldwide Cosmetic Surgery and Procedure Industry is Expected to Reach $107.2 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 3, 2022
Health, Other Health, Ill, Tempo, Head, Microbiota, Overactive bladder, Knowledge, Beauty, Radio, Patient, Botulism, Advertising, Toxin (comics), Injection, Forehead, Neck, Plastic surgery, Informal economy, Spasm, Medicine, Muscle, Facial muscles, Services marketing, Hyperhidrosis, Skin, Enzyme, Torticollis, CAGR, Dentistry, Canning, Health insurance, Botulinum toxin, Botulinum toxin

The Global Cosmetic Surgery And Procedure Market size is expected to reach $107.2 billion by 2027, rising at a market growth of 9.8% CAGR during the forecast period.

Key Points: 
  • The Global Cosmetic Surgery And Procedure Market size is expected to reach $107.2 billion by 2027, rising at a market growth of 9.8% CAGR during the forecast period.
  • Cosmetic surgery is a specialized area of medicine that focuses on enhancing one's look through surgical and medicinal methods.
  • In addition, cosmetic surgery is opted by the people who want to increase the aesthetic appeal of a functional body part.
  • The invention of new cosmetic devices through manufactures has resulted in an increase in demand for cosmetic therapies in recent years.